Viking Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Viking Therapeutics, Inc. (VKTX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$203.52 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-11
- Viking Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$203.52M.
- Viking Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$105.86M.
- Viking Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$84.87M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$203.52M 10-K · filed 2026-02-11 |
| 2024-12-31 | -$105.86M 10-K · filed 2026-02-11 |
| 2023-12-31 | -$84.87M 10-K · filed 2026-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |